Eric Yuen

Eric Yuen has extensive work experience in the biotechnology and pharmaceutical industry. Eric is the Co-founder and Chief Medical Officer of Spirovant Sciences, Inc., where they focus on developing AAV and lentiviral gene therapies for cystic fibrosis. Prior to this, they were a Consultant to various biotechnology and pharmaceutical companies, assisting with the development of enzyme replacement therapy, gene therapy, monoclonal antibodies, and small molecules for diseases such as Alzheimer's disease, cystic fibrosis, glaucoma, and Pompe disease. Eric also served as a Board Director for Asceneuron SA and as a Scientific Advisory Board member for Nitrome Biosciences, Inc. Previously, they held positions as the Chief Medical Officer at Inozyme Pharma, Inc., the Vice President of Clinical Development at BioClin Therapeutics, Inc., and the Vice President of Scientific Licensing and Therapeutic Area Head for CNS Clinical Development at Johnson & Johnson. Eric Yuen also has experience as the Head of Clinical Development at Janssen Alzheimer Immunotherapy, overseeing the development of therapies for Alzheimer's disease. Eric holds a prominent role in the industry and has made significant contributions to the field of biotechnology and pharmaceuticals.

Eric Yuen attended Stanford University from 1981 to 1985, where they completed their Bachelor of Science (B.S.) degree in Physics and Biology. Afterward, from 1985 to 1989, they attended The University of Chicago Pritzker School of Medicine and obtained their Doctor of Medicine (M.D.) degree.